首页> 外文期刊>Hypertension research: Official journal of the Japanese Society of Hypertension >Impact of metabolic syndrome among patients with and without diabetes mellitus on long-term outcomes after percutaneous coronary intervention.
【24h】

Impact of metabolic syndrome among patients with and without diabetes mellitus on long-term outcomes after percutaneous coronary intervention.

机译:经皮冠状动脉介入治疗后有无糖尿病患者的代谢综合征对长期预后的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Metabolic syndrome (MS) is highly prevalent and an established key risk factor for coronary artery disease, regardless of the presence or absence of diabetes mellitus (DM). Long-term follow-up studies have addressed the influence of MS with and without DM on the prognosis of patients undergoing percutaneous coronary intervention (PCI). We classified 748 consecutive patients who had undergone PCI into four groups as follows: neither DM nor MS, DM alone, MS alone, and both DM and MS. Post hoc analyses were conducted using prospectively collected clinical data. Multivariate Cox regression was used to evaluate the risk within each group for all-cause mortality and composite cardiac events (cardiac death, non-fatal acute coronary syndrome), adjusting for age, gender, body mass index, low-density lipoprotein (LDL) cholesterol level, hypertension, smoking, prior coronary artery bypass graft, presentation of acute coronary syndrome, left ventricular ejection fraction, multivessel disease, and procedural success. The progress of 321 (42.9%) patients with neither DM nor MS, 109 (14.6%) patients with DM alone, 129 (17.2%) patients with MS alone, and 189 (25.3%) patients with both DM and MS was followed up for a mean of 12.0+/-3.6 years. Patients with both DM and MS had significant risk for increased all-cause mortality (2.10 [1.19-3.70]). Patients with MS alone (2.14 [1.31-3.50]) and with both DM and MS (1.87 [1.18-2.96]) were at significant risk for increased cardiac events. In conclusion, the risk of cardiac events is significantly increased in patients with metabolic syndrome following PCI, irrespective of DM.
机译:无论是否存在糖尿病(DM),代谢综合征(MS)都是非常普遍的疾病,并且是确定的冠状动脉疾病关键危险因素。长期的随访研究已经探讨了有或无DM的MS对经皮冠状动脉介入治疗(PCI)患者预后的影响。我们将748例接受PCI手术的连续患者分为以下四类:DM和MS,仅DM,仅MS,以及DM和MS。使用前瞻性收集的临床数据进行事后分析。多元Cox回归用于评估各组内全因死亡率和复合心脏事件(心脏死亡,非致命性急性冠状动脉综合征)的风险,并根据年龄,性别,体重指数,低密度脂蛋白(LDL)进行调整胆固醇水平,高血压,吸烟,先行冠状动脉搭桥术,急性冠状动脉综合征,左心室射血分数,多支血管疾病和手术成功的表现。随访了321名(42.9%)既无DM又无MS的患者,109名(14.6%)仅有DM的患者,129名(17.2%)仅有MS的患者和189名(25.3%)既有DM又有MS的患者的进展平均为12.0 +/- 3.6年。 DM和MS患者均具有因全因死亡率增加的显着风险(2.10 [1.19-3.70])。单纯MS患者(2.14 [1.31-3.50])以及DM和MS患者(1.87 [1.18-2.96])患心脏事件增加的风险很高。综上所述,PCI后发生代谢综合征的患者,不论DM,心脏病事件的风险均显着增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号